Encouraging progress on BD, litigation, and clinical front Opens for making NEX-18 superior to Vidaza Co. sees good opportunities for securing needed funding
Pushes and pulls in Biden’s Inflation Reduction Act 2022 Max impact ’26–early ’30s, possible mitigations thereafter Negative but manageable for AZN, biotech largely spared
New pilot plant lays foundation for licensing agreements NEX-18 programme pause pushes approvals to ‘28 Updated valuation with new fair value range of SEK 3-9
Claims vaccine-developer infringes several patents Initial assessment suggests suit has potential Amicable solution probable but raises some uncertainty